These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
886 related items for PubMed ID: 14974743
1. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Yoshiyama T, Yanai H, Rhiengtong D, Palittapongarnpim P, Nampaisan O, Supawitkul S, Uthaivorawit W, Mori T. Int J Tuberc Lung Dis; 2004 Jan; 8(1):31-8. PubMed ID: 14974743 [Abstract] [Full Text] [Related]
2. [Process of acquiring drug resistance: retrospective review of records of MDR TB]. Yoshiyama T, Ito K, Ogata H, Mitarai S, Hoshino H, Okumura M, Aman K, Aono A, Wada M. Kekkaku; 2004 Dec; 79(12):717-24. PubMed ID: 15782617 [Abstract] [Full Text] [Related]
3. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. Yoshiyama T, Ogata H, Ito K, Aono A, Wada M. Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318 [Abstract] [Full Text] [Related]
4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H. Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [Abstract] [Full Text] [Related]
6. [Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis]. Yoshiyama T, Ito K, Ogata H, Aono A, Wada M. Kekkaku; 2005 Jan; 80(1):9-14. PubMed ID: 15839057 [Abstract] [Full Text] [Related]
7. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance. Shamaei M, Marjani M, Chitsaz E, Kazempour M, Esmaeili M, Farnia P, Tabarsi P, Amiri MV, Mirsaeidi M, Mansouri D, Masjedi MR, Velayati AA. Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897 [Abstract] [Full Text] [Related]
8. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Park SK, Kim JH, Kang H, Cho JS, Smego RA. Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342 [Abstract] [Full Text] [Related]
9. Prevalence of drug resistance in Thai human immunodeficiency virus seropositive tuberculosis patients. Hongthiamthong P, Chuchottaworn C, Amatayakul N. J Med Assoc Thai; 1994 Jul; 77(7):363-7. PubMed ID: 7876754 [Abstract] [Full Text] [Related]
10. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, Werner B, Sloutsky A, Timperi R, Wilson ME, Pagano M, Farmer PE. Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087 [Abstract] [Full Text] [Related]
11. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571 [Abstract] [Full Text] [Related]
12. Prevalence of drug-resistant tuberculosis in an HIV endemic area in northern Thailand. Yoshiyama T, Supawitkul S, Kunyanone N, Riengthong D, Yanai H, Abe C, Ishikawa N, Akarasewi P, Payanandana V, Mori T. Int J Tuberc Lung Dis; 2001 Jan; 5(1):32-9. PubMed ID: 11263513 [Abstract] [Full Text] [Related]
13. The management of tuberculosis: epidemiology, resistance and monitoring. Bang D. Dan Med Bull; 2010 Nov; 57(11):B4213. PubMed ID: 21055374 [Abstract] [Full Text] [Related]
14. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital. Meskel DW, Abate G, Lakew M, Goshu S, Aseffa A. Ethiop Med J; 2008 Jul; 46(3):219-25. PubMed ID: 19271385 [Abstract] [Full Text] [Related]
15. [Mycobacterium tuberculosis resistance to antitubercular agents in Antananarivo in 2000]. Ratsirahonana O, Rasolofo Razanamparany V, Rasolonavalona T, Rakotonirina V, Rakotoarisaonina A, Rakotoherisoa A, Ralamboson M, Cauchoix B, Rakotondramarina D, Ramarokoto H. Arch Inst Pasteur Madagascar; 2002 Jul; 68(1-2):44-7. PubMed ID: 12643091 [Abstract] [Full Text] [Related]
16. Drug resistance monitoring: combined rates may be the best indicator of programme performance. Van Deun A, Salim AH, Daru P, Das AP, Aung KJ, Hossain MA, Rigouts L, Fissette K, Portaels F. Int J Tuberc Lung Dis; 2004 Jan; 8(1):23-30. PubMed ID: 14974742 [Abstract] [Full Text] [Related]
17. Prevalence of acquired MDR-TB and HIV co-infection. Deivanayagam CN, Rajasekaran S, Venkatesan R, Mahilmaran A, Ahmed PR, Annadurai S, Kumar S, Chandrasekar C, Ravichandran N, Pencillaiah R. Indian J Chest Dis Allied Sci; 2002 Jan; 44(4):237-42. PubMed ID: 12437236 [Abstract] [Full Text] [Related]
18. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Abate G, Miörner H, Ahmed O, Hoffner SE. Int J Tuberc Lung Dis; 1998 Jul; 2(7):580-4. PubMed ID: 9661826 [Abstract] [Full Text] [Related]
19. Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme. Al-Marri MR. Int J Tuberc Lung Dis; 2001 Dec; 5(12):1116-21. PubMed ID: 11769769 [Abstract] [Full Text] [Related]